Literature DB >> 28754673

Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation.

Yi Yin1, Rui Li2, Kangling Xu3, Sentai Ding2,4, Jeffrey Li2, GuemHee Baek5, Susmita G Ramanand5, Sam Ding2, Zhao Liu2,4, Yunpeng Gao5, Mohammed S Kanchwala6, Xiangyi Li5, Ryan Hutchinson2, Xihui Liu2, Solomon L Woldu2, Chao Xing6, Neil B Desai3, Felix Y Feng7,8,9, Sandeep Burma3, Johann S de Bono10, Scott M Dehm11, Ram S Mani2,5, Benjamin P C Chen3, Ganesh V Raj1,12.   

Abstract

In prostate cancer, androgen deprivation therapy (ADT) enhances the cytotoxic effects of radiotherapy. This effect is associated with weakening of the DNA damage response (DDR) normally supported by the androgen receptor. As a significant number of patients will fail combined ADT and radiotherapy, we hypothesized that DDR may be driven by androgen receptor splice variants (ARV) induced by ADT. Investigating this hypothesis, we found that ARVs increase the clonogenic survival of prostate cancer cells after irradiation in an ADT-independent manner. Notably, prostate cancer cell irradiation triggers binding of ARV to the catalytic subunit of the critical DNA repair kinase DNA-PK. Pharmacologic inhibition of DNA-PKc blocked this interaction, increased DNA damage, and elevated prostate cancer cell death after irradiation. Our findings provide a mechanistic rationale for therapeutic targeting of DNA-PK in the context of combined ADT and radiotherapy as a strategy to radiosensitize clinically localized prostate cancer. Cancer Res; 77(18); 4745-54. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28754673      PMCID: PMC5600864          DOI: 10.1158/0008-5472.CAN-17-0164

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Cloud CPFP: a shotgun proteomics data analysis pipeline using cloud and high performance computing.

Authors:  David C Trudgian; Hamid Mirzaei
Journal:  J Proteome Res       Date:  2012-10-29       Impact factor: 4.466

2.  Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.

Authors:  Ziyang Yu; Sen Chen; Adam G Sowalsky; Olga S Voznesensky; Elahe A Mostaghel; Peter S Nelson; Changmeng Cai; Steven P Balk
Journal:  Clin Cancer Res       Date:  2014-01-21       Impact factor: 12.531

3.  Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.

Authors:  Stephanie O Peacock; Cale D Fahrenholtz; Kerry L Burnstein
Journal:  Mol Endocrinol       Date:  2012-09-28

4.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  N Engl J Med       Date:  2014-09-03       Impact factor: 91.245

5.  GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.

Authors:  Bin He; Rainer B Lanz; Warren Fiskus; Chuandong Geng; Ping Yi; Sean M Hartig; Kimal Rajapakshe; John Shou; Liping Wei; Shrijal S Shah; Christopher Foley; Sue Anne Chew; Vijay K Eedunuri; Diego J Bedoya; Qin Feng; Takashi Minami; Constantine S Mitsiades; Anna Frolov; Nancy L Weigel; Susan G Hilsenbeck; Daniel G Rosen; Timothy Palzkill; Michael M Ittmann; Yongcheng Song; Cristian Coarfa; Bert W O'Malley; Nicholas Mitsiades
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

6.  TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.

Authors:  Michael D Nyquist; Yingming Li; Tae Hyun Hwang; Luke S Manlove; Robert L Vessella; Kevin A T Silverstein; Daniel F Voytas; Scott M Dehm
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-07       Impact factor: 11.205

7.  Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation.

Authors:  Daniel E Spratt; Michael J Evans; Brian J Davis; Michael G Doran; Man Xia Lee; Neel Shah; John Wongvipat; Kathryn E Carnazza; George G Klee; William Polkinghorn; Donald J Tindall; Jason S Lewis; Charles L Sawyers
Journal:  Cancer Res       Date:  2015-10-02       Impact factor: 12.701

8.  Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies.

Authors:  Siu Chiu Chan; Luke A Selth; Yingming Li; Michael D Nyquist; Lu Miao; James E Bradner; Ganesh V Raj; Wayne D Tilley; Scott M Dehm
Journal:  Nucleic Acids Res       Date:  2015-04-23       Impact factor: 16.971

9.  Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer.

Authors:  Christine Henzler; Yingming Li; Rendong Yang; Terri McBride; Yeung Ho; Cynthia Sprenger; Gang Liu; Ilsa Coleman; Bryce Lakely; Rui Li; Shihong Ma; Sean R Landman; Vipin Kumar; Tae Hyun Hwang; Ganesh V Raj; Celestia S Higano; Colm Morrissey; Peter S Nelson; Stephen R Plymate; Scott M Dehm
Journal:  Nat Commun       Date:  2016-11-29       Impact factor: 14.919

10.  Androgen receptor signaling regulates DNA repair in prostate cancers.

Authors:  William R Polkinghorn; Joel S Parker; Man X Lee; Elizabeth M Kass; Daniel E Spratt; Phillip J Iaquinta; Vivek K Arora; Wei-Feng Yen; Ling Cai; Deyou Zheng; Brett S Carver; Yu Chen; Philip A Watson; Neel P Shah; Sho Fujisawa; Alexander G Goglia; Anuradha Gopalan; Haley Hieronymus; John Wongvipat; Peter T Scardino; Michael J Zelefsky; Maria Jasin; Jayanta Chaudhuri; Simon N Powell; Charles L Sawyers
Journal:  Cancer Discov       Date:  2013-09-11       Impact factor: 39.397

View more
  20 in total

1.  Prostate cancer: A variety of therapy: ARVs mediate DDR.

Authors:  Louise Stone
Journal:  Nat Rev Urol       Date:  2017-08-16       Impact factor: 14.432

2.  Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.

Authors:  Payel Chatterjee; Michael T Schweizer; Jared M Lucas; Ilsa Coleman; Michael D Nyquist; Sander B Frank; Robin Tharakan; Elahe Mostaghel; Jun Luo; Colin C Pritchard; Hung-Ming Lam; Eva Corey; Emmanuel S Antonarakis; Samuel R Denmeade; Peter S Nelson
Journal:  J Clin Invest       Date:  2019-07-16       Impact factor: 14.808

Review 3.  Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.

Authors:  Alejandro Athie; Sara Arce-Gallego; Macarena Gonzalez; Rafael Morales-Barrera; Cristina Suarez; Teresa Casals Galobart; Gonzalo Hernandez Viedma; Joan Carles; Joaquin Mateo
Journal:  Curr Oncol Rep       Date:  2019-03-27       Impact factor: 5.075

Review 4.  Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer.

Authors:  Edina C Wang; W Robert Lee; Andrew J Armstrong
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-10-06       Impact factor: 5.455

5.  Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor-positive Prostate and Breast Cancers.

Authors:  Amy H Tien; Marianne D Sadar
Journal:  Mol Cancer Ther       Date:  2021-11-23       Impact factor: 6.009

6.  Mithramycin suppresses DNA damage repair via targeting androgen receptor in prostate cancer.

Authors:  Shan Wang; Collin Gilbreath; Rahul K Kollipara; Rajni Sonavane; Xiaofang Huo; Paul Yenerall; Amit Das; Shihong Ma; Ganesh V Raj; Ralf Kittler
Journal:  Cancer Lett       Date:  2020-05-30       Impact factor: 8.679

7.  Proliferating cell nuclear antigen directly interacts with androgen receptor and enhances androgen receptor‑mediated signaling.

Authors:  Shan Lu; Zhongyun Dong
Journal:  Int J Oncol       Date:  2021-05-13       Impact factor: 5.650

8.  The Role of Crosstalk between AR3 and E2F1 in Drug Resistance in Prostate Cancer Cells.

Authors:  Jin Xu; Xi Yang; Dhanraj Deshmukh; Hegang Chen; Shengyun Fang; Yun Qiu
Journal:  Cells       Date:  2020-04-28       Impact factor: 6.600

9.  AR phosphorylation and CHK2 kinase activity regulates IR-stabilized AR-CHK2 interaction and prostate cancer survival.

Authors:  Huy Q Ta; Natalia Dworak; Melissa L Ivey; Devin G Roller; Daniel Gioeli
Journal:  Elife       Date:  2020-06-24       Impact factor: 8.140

10.  Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.

Authors:  Katharina Lückerath; Liu Wei; Wolfgang P Fendler; Susan Evans-Axelsson; Andreea D Stuparu; Roger Slavik; Christine E Mona; Jeremie Calais; Matthew Rettig; Robert E Reiter; Ken Herrmann; Caius G Radu; Johannes Czernin; Matthias Eiber
Journal:  EJNMMI Res       Date:  2018-10-29       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.